PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

BACKGROUND: Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. However, associations between PIK3CA mutation status...

Descripción completa

Detalles Bibliográficos
Autores principales: Fillbrunn, Mirko, Signorovitch, James, André, Fabrice, Wang, Iris, Lorenzo, Ines, Ridolfi, Antonia, Park, Jinhee, Dua, Akanksha, Rugo, Hope S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490901/
https://www.ncbi.nlm.nih.gov/pubmed/36131248
http://dx.doi.org/10.1186/s12885-022-10078-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490901/
https://www.ncbi.nlm.nih.gov/pubmed/36131248
http://dx.doi.org/10.1186/s12885-022-10078-5

Ejemplares similares